Home » Stocks » Pfizer

Pfizer Inc. (PFE)

Stock Price: $36.00 USD -0.25 (-0.69%)
Updated Sep 23, 2020 4:02 PM EDT - Market closed
Pre-market: $35.80 -0.20 (-0.56%) Sep 24, 6:15 AM

Stock Price Chart

Key Info

Market Cap 200.05B
Revenue (ttm) 49.20B
Net Income (ttm) 14.17B
Shares Out 5.56B
EPS (ttm) 2.53
PE Ratio 14.23
Forward PE 11.98
Dividend $1.52
Dividend Yield 4.22%

Stock Quote

Trading Day Sep 23, 2020
Last Price $36.00
Previous Close $36.25
Change ($) -0.25
Change (%) -0.69%
Day's Open 36.30
Day's Range 35.97 - 36.38
Day's Volume 21,562,861
52-Week Range 27.88 - 40.97

More Stats

Market Cap 200.05B
Enterprise Value 240.87B
Earnings Date (est) Oct 27, 2020
Ex-Dividend Date Jul 30, 2020
Shares Outstanding 5.56B
Float 5.55B
EPS (basic) 2.55
EPS (diluted) 2.53
FCF / Share 2.27
Dividend $1.52
Dividend Yield 4.22%
Earnings Yield 7.03%
FCF Yield 6.30%
Payout Ratio n/a
Shares Short 45.21M
Short Ratio 2.10
Short % of Float 0.81%
Beta 0.66
PE Ratio 14.23
Forward PE 11.98
P/FCF Ratio 15.87
PS Ratio 4.07
PB Ratio 3.18
Revenue 49.20B
Operating Income 8.96B
Net Income 14.17B
Free Cash Flow 12.60B
Net Cash -40.82B
Net Cash / Share -7.35
Gross Margin 84.84%
Operating Margin 18.22%
Profit Margin 28.80%
FCF Margin 25.62%
ROA 5.49%
ROE 22.81%
ROIC 18.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 6
Overweight 2
Hold 8
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$42.08*
(16.89% upside)
Low
35.0
Current: $36.00
High
53.0
Target: 42.08
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue51,75053,64752,54652,82448,85149,60551,58454,65761,03565,165
Revenue Growth-3.54%2.1%-0.53%8.13%-1.52%-3.84%-5.62%-10.45%-6.34%-
Gross Profit41,53142,39941,31840,50239,20340,02841,99844,83648,53550,377
Operating Income9,59611,88512,3068,3518,96412,24015,71611,24211,4819,471
Net Income16,27311,15321,3087,2156,9609,13522,00314,57010,0098,257
Shares Outstanding5,5695,8725,9706,0896,1766,3466,8137,4427,8178,036
Earnings Per Share2.871.873.521.171.111.423.191.941.271.02
EPS Growth53.48%-46.88%200.85%5.41%-21.83%-55.49%64.43%52.76%24.51%-
Dividend Per Share1.441.361.281.201.121.040.960.880.800.72
Dividend Growth5.88%6.25%6.67%7.14%7.69%8.33%9.09%10%11.11%-
Operating Cash Flow12,58815,82716,80216,19214,68817,08417,68416,74620,24011,454
Capital Expenditures-2,594-2,196-2,217-1,999-1,496-1,583-1,465-1,419-1,882-1,513
Free Cash Flow9,99413,63114,58514,19313,19215,50116,21915,32718,3589,941
Cash & Equivalents9,83018,83319,99217,85023,29036,12232,40832,39926,45228,479
Total Debt52,15041,74043,49142,08638,89936,68236,48937,46038,94244,013
Net Cash / Debt-42,320-22,907-23,499-24,236-15,609-560-4,081-5,061-12,490-15,534
Assets167,489159,422171,797171,615167,381167,566172,101185,798188,002195,014
Liabilities104,04295,664100,141111,776102,38495,94495,481104,120105,381106,749
Book Value63,14363,40771,30859,54464,72071,30176,30781,26082,19087,813
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pfizer Inc.
Country United States
Employees 88,300
CEO Albert Bourla

Stock Information

Ticker Symbol PFE
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: PFE

Description

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and research collaboration and license agreement with BioInvent International AB. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.